Evidence map›Paper›PMID 19156517›Full record

ArticleGlycoconjugate journal2009

N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer.

Akira Seko, Fumio Kataoka, Daisuke Aoki, Masaru Sakamoto, Toshiaki Nakamura, Masayuki Hatae, Suguru Yonezawa, Katsuko Yamashita

Abstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Akira SekoInnovative Research Initiatives, Tokyo Institute of Technology, Yokohama, Japan.
Fumio Kataoka
Daisuke Aoki
Masaru Sakamoto
Toshiaki Nakamura
Masayuki Hatae
Suguru Yonezawa
Katsuko Yamashita
Kagoshima City Hospital · JPKeio University · JPTokyo Institute of Technology · JPKagoshima University · JPSasaki Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N-Acetylglucosamine 6-O-sulfotransferase-2 (GlcNAc6ST2) is ectopically expressed in ovarian mucinous and clear cell adenocarcinoma [Kanoh et al., Glycoconj J 23:453-460, 2006]. Here we studied whether GlcNAc6ST2 protein can be detected in sera from patients with gynecological cancers and could serve as a tumor marker. First, we created a monoclonal antibody and polyclonal antiserum against GlcNAc6ST2. These antibodies were specific for GlcNAc6ST2, as shown by Western blot analysis and immunoprecipitation. Using these antibodies, we constructed a sandwich ELISA method for detecting GlcNAc6ST2 in the serum. GlcNAc6ST2 provided lower positive rates for ovarian cancer than CA125, but higher positive rates for uterine cervical and corpus cancer than SCC antigens and CA125, respectively. A significantly higher percentage of stage I uterine cervical and corpus cancers were positive for GlcNAc6ST2 than for SCC antigens and CA125, respectively. GlcNAc6ST2 could therefore be a good serological marker for detecting early-stage uterine cervical and corpus cancers.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorCarbohydrate SulfotransferasesCorpus LuteumEnzyme-Linked Immunosorbent AssayFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsReference StandardsSulfotransferasesAntibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorCarbohydrate SulfotransferasesSulfotransferases

Identifiers

PMID19156517
OpenAlexW1975619857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.